Disc Medicine (IRON) Stock Still Looks Pricey As Book Value Lags Expectations
Disc Medicine shares have retreated sharply over the past year, and that slide puts a spotlight on a simple question for holders and would-be buyers: Is the current price still in line with what the company’s balance sheet and book value can reasonably support? The stock is down 36.8% over the past 12 months, which makes it important to check whether the recent drop has brought the valuation closer to what its underlying net assets suggest. Disc Medicine focuses on developing therapies in...

What's Your Reaction?









